Cargando…
Antifibrotic drugs as therapeutic tools in resistant melanoma
Melanoma is the most aggressive form of skin cancer. Together with the recent advances in immunotherapy, targeted therapy with inhibitors of the Mitogen Activated Protein Kinase (MAPKi) pathway including BRAF and MEK inhibitors has greatly improved the clinical outcome of these patients. Unfortunate...
Autores principales: | Sanchez‐Laorden, Berta, Nieto, M Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8899909/ https://www.ncbi.nlm.nih.gov/pubmed/35156326 http://dx.doi.org/10.15252/emmm.202115449 |
Ejemplares similares
-
Turning a pathogen protein into a therapeutic tool for sepsis
por: Vanderhaeghen, Tineke, et al.
Publicado: (2020) -
A novel combination treatment against melanoma with NRAS mutation and therapy resistance
por: Yu, Yanlin
Publicado: (2018) -
Altruistic cell death and collective drug resistance
por: Carmona-Fontaine, Carlos, et al.
Publicado: (2012) -
Beating tumour drug resistance: “Lamarckian” induction in the spotlight
por: Robles‐Espinoza, Carla Daniela
Publicado: (2018) -
Desmoplastic melanoma: C>Ts and NF‐κB
por: Rabbie, Roy, et al.
Publicado: (2016)